RPL27A Antibody

What is RPL27A and what are its core cellular functions?

RPL27A (Ribosomal Protein L27a) is a component of the large ribosomal subunit (60S) essential for protein synthesis. In humans, the canonical protein consists of 148 amino acid residues with a molecular mass of 16.6 kDa, though it typically appears around 18-19 kDa on Western blots . It is primarily localized in the cytoplasm and widely expressed across diverse tissue types .

Beyond its structural role in ribosomes, RPL27A has several critical functions:

• Required for proper rRNA processing and maturation of 28S and 5.8S rRNAs

• Involved in p53 signaling pathways and cell cycle regulation

• Targeted by miR-595, suggesting post-transcriptional regulation

RPL27A belongs to the Universal ribosomal protein uL15 family, with common synonyms including uL15, 60S ribosomal protein L27a, and large ribosomal subunit protein uL15 .

How can I select the appropriate RPL27A antibody for my experiment?

Selecting the optimal RPL27A antibody requires evaluating multiple parameters:

When possible, select antibodies with comprehensive validation data, including knockdown/knockout validation, which provides strong evidence of specificity .

What are the recommended protocols for Western blot detection of RPL27A?

For optimal Western blot detection of RPL27A, follow these evidence-based recommendations:

Sample Preparation and Loading:

• Use NETN lysis buffer for efficient protein extraction

• Load 30-50 μg of total protein per lane for cell lysates

• Use 12-15% SDS-PAGE gels due to the small size of RPL27A (16.6-19 kDa)

Antibody Dilutions and Conditions:

• Primary antibody: Dilutions typically range from 1:200-1:1000

  • Proteintech 16002-1-AP: 1:200-1:1000

  • Abcam ab74731: 1:500

• Incubate primary antibody overnight at 4°C for best results

• Expected band size: 16-19 kDa (primary band)

  • Note: Some antibodies may detect additional bands, such as a 38 kDa band with ab74731, potentially representing dimers

Controls:

• Include positive controls: A549, HeLa, HEK-293T, or Jurkat cells all express detectable levels of RPL27A

• Peptide competition controls can confirm specificity, as demonstrated with ab74731

How should I optimize immunohistochemistry protocols for RPL27A detection?

For successful immunohistochemical detection of RPL27A:

Antigen Retrieval (Critical Step):

• Use TE buffer pH 9.0 as the primary method

• Alternatively, citrate buffer pH 6.0 may be used, though potentially with reduced efficacy

Antibody Dilutions:

• Most IHC-validated RPL27A antibodies work optimally at 1:250-1:1000

• Example: Proteintech 16002-1-AP is recommended at 1:250-1:1000 for IHC applications

Tissue-Specific Considerations:

• Positive control: Mouse stomach tissue has been validated as a reliable positive control

• Human colon cancer tissue has also been successfully stained for RPL27A

Background Reduction:

• Extend blocking time to 1-2 hours with 5-10% normal serum

• Include 0.1-0.3% Triton X-100 or Tween-20 in washing and antibody dilution buffers

• Increase the number and duration of washes between antibody incubations

What controls are essential when working with RPL27A antibodies?

Comprehensive controls ensure reliable RPL27A detection:

In published studies, peptide competition assays have effectively demonstrated RPL27A antibody specificity, with specific signal disappearing upon peptide pre-incubation .

How can RPL27A knockdown be utilized to study p53 signaling pathways?

RPL27A knockdown provides a powerful tool for investigating p53 pathway dynamics:

Experimental Approach:

• Use shRNA constructs like RPL27A-sh2 (80% knockdown) and RPL27A-sh4 (40% knockdown)

• Compare effects in p53-positive cells (HCT-116, HEL) and p53-null cells (K562, U937)

• Measure multiple readouts of p53 activation:

  • p53 mRNA and protein levels

  • MDM2 expression (typically reduced)

  • p21 and Bax transcripts (typically increased)

  • Cellular phenotypes: apoptosis, cell cycle arrest

Key Research Findings:

• RPL27A knockdown in p53-expressing HCT-116 cells significantly increased p53 mRNA levels (p=0.005)

• RPL27A interacts with MDM2 and RPL5 as demonstrated by co-immunoprecipitation assays

• RPL27A depletion induced apoptosis in both p53-expressing (55% early apoptosis) and p53-null cells, though with stronger effects in p53-positive cells

• In CD34+ cells, RPL27A knockdown increased p53 protein levels despite decreased p53 mRNA, suggesting post-transcriptional regulation

This system provides insights into ribosomal stress responses and p53 activation mechanisms, particularly when compared with other ribosomal protein knockdowns (RPS14, RPL5).

What is the relationship between RPL27A and miR-595, and how can it be studied?

The RPL27A/miR-595 regulatory axis represents an important post-transcriptional mechanism:

Experimental Evidence:

• RPL27A was identified as a direct target of miR-595 using a 3'UTR cDNA target ID library in MCF7 cells

• miR-595 overexpression significantly decreased RPL27A expression:

  • 83% reduction in KG-1 cells

  • 73% reduction in K562 cells

  • 88% reduction in HeLa cells

  • 55% reduction in HepG2 cells

• This effect was reversible using a hairpin inhibitor against miR-595

Research Methods:

• miR-595 Modulation:

  • Overexpression: Transfection with pBabepuro-miR-595 followed by puromycin selection

  • Inhibition: Transfection with miR-595-specific hairpin inhibitors

• RPL27A Assessment:

  • mRNA quantification via qPCR

  • Protein analysis via Western blotting

• Functional Outcomes:

  • p53 pathway activation

  • Cell proliferation effects

  • Apoptosis assays

Clinical Relevance:
In myelodysplastic syndrome patients, miR-595 expression appeared lower in high-risk disease compared to low-risk disease, with corresponding higher RPL27A expression in high-risk disease .

How does RPL27A contribute to ribosome synthesis and nucleolar integrity?

RPL27A plays multiple roles in ribosome biogenesis beyond its structural function:

Key Functions:

• rRNA Processing: Required for proper processing and maturation of 28S and 5.8S rRNAs

• Nucleolar Organization: RPL27A depletion causes abnormal dispersion of fibrillarin in the nucleolus, indicating a role in maintaining nucleolar structure

• Ribosomal Subunit Assembly: As a component of the 60S subunit, contributes to large subunit maturation

Experimental Findings:

• Cells infected with RPL27A-shRNA show disrupted nucleolar architecture when stained with anti-fibrillarin antibody

• RPL27A knockdown affects cell proliferation in multiple cell lines through both p53-dependent and p53-independent mechanisms

• In CD34+ cells, RPL27A deficiency particularly impacts erythroid differentiation, with significant reductions in both immature and mature erythroid cells

These findings connect RPL27A to broader cellular processes beyond translation, positioning it within the network of ribosomal proteins with extraribosomal functions.

Why might multiple bands appear in RPL27A Western blots, and how should they be interpreted?

Multiple bands in RPL27A Western blots can occur for several mechanistic reasons:

Verification Approaches:

• Peptide competition assays: Pre-incubate antibody with immunizing peptide to identify specific bands

• Knockdown validation: Bands representing true RPL27A should diminish with RPL27A-specific shRNA treatment

• Multiple antibody comparison: Use antibodies targeting different epitopes to cross-validate bands

Based on published data, the most reliable RPL27A signal typically appears at 16-19 kDa, though dimerization or modifications may produce legitimate higher-weight bands .

How should differences in RPL27A expression across tissue and cell types be interpreted?

Variations in RPL27A expression require careful interpretation considering multiple biological factors:

Normal Tissue Distribution:

• RPL27A is widely expressed across many tissue types

• Expression levels may correlate with protein synthesis requirements of specific tissues

Cell State Considerations:

• Proliferating cells typically show higher RPL27A expression than quiescent cells

• Differentiation status may influence expression patterns, as observed in CD34+ erythroid differentiation studies

Disease Context:

• In myelodysplastic syndrome, RPL27A was significantly upregulated in patients with -7/7q- compared to 5q- patients

• RPL27A expression appears higher in high-risk vs. low-risk MDS, inversely correlating with miR-595 levels

Quantification Recommendations:

• For Western blot: Normalize to total protein rather than single housekeeping genes

• For immunostaining: Use digital image analysis with appropriate cellular segmentation

• For qPCR: Employ multiple reference genes and geometric mean normalization

Researchers should consider the broader context of ribosome biogenesis regulation rather than viewing RPL27A in isolation.

What phenotypes result from RPL27A depletion in different experimental systems?

RPL27A depletion produces diverse phenotypes depending on the cellular context:

In Cancer Cell Lines:

• Significant reduction in cell proliferation across multiple cell lines

• Increased apoptosis:

  • 55% early apoptosis in p53-positive HCT-116 cells with RPL27A-sh2

  • 15-20% apoptosis in p53-null K562 cells

• Nucleolar disruption, visualized by abnormal fibrillarin dispersion

• p53 activation with corresponding reduction in MDM2 levels

In Primary CD34+ Cells:

• Attenuated cellular proliferation (hypophosphorylation of Rb protein)

• Increased p53 protein expression and upregulation of p21 and Bax transcripts

• Marked reduction in both immature and mature erythroid cells

• Significant inhibition of erythroid and granulocyte/macrophage colony formation

In Animal Models:

• A mouse model with low Rpl27a expression (sooty foot ataxia mouse) exhibits p53-dependent phenotypes including hyperpigmentation

• Hematological abnormalities documented by complete blood counts

The differential effects observed in p53-positive versus p53-negative backgrounds indicate both p53-dependent and p53-independent mechanisms contribute to RPL27A depletion phenotypes.

How might RPL27A be exploited as a therapeutic target in disease?

Based on current research findings, RPL27A presents several potential therapeutic applications:

In Cancer:

• Given RPL27A's role in p53 activation, targeted depletion could potentially enhance p53-mediated tumor suppression in p53-intact cancers

• The interaction between RPL27A and MDM2 suggests potential for disrupting this interaction to activate p53

• RPL27A modulation could sensitize cancer cells to existing therapeutics that induce ribosomal stress

In Hematological Disorders:

• In myelodysplastic syndrome, where RPL27A may be overexpressed in high-risk disease, targeted reduction could potentially slow disease progression

• Given RPL27A's impact on erythroid differentiation, modulation might address specific erythroid defects in certain blood disorders

Potential Therapeutic Approaches:

• miR-595 mimics to reduce RPL27A expression in diseases with RPL27A overexpression

• Small molecule inhibitors targeting RPL27A-MDM2 interaction

• Antisense oligonucleotides to modulate RPL27A expression

Research Considerations:

• The essential nature of RPL27A for cellular function necessitates careful targeting strategies

• The observation that even 40% knockdown (with RPL27A-sh4) induces biological effects suggests partial inhibition may be sufficient

• Exploitation of tissue-specific regulation mechanisms could help achieve selective targeting

What are the most promising technical advances for studying RPL27A function?

Emerging technologies offer new opportunities for RPL27A research:

CRISPR/Cas9 Applications:

• Generation of conditional/inducible RPL27A knockout models to study temporal aspects of RPL27A function

• Endogenous tagging of RPL27A for live-cell imaging without overexpression artifacts

• Base editing or prime editing for introduction of specific mutations to study structure-function relationships

Proteomics Approaches:

• Proximity labeling methods (BioID, APEX) to identify RPL27A interaction partners in different cellular compartments

• Ribosome profiling to investigate translational impacts of RPL27A modulation

• Protein turnover analysis to understand RPL27A stability and regulation

Advanced Imaging:

• Super-resolution microscopy to visualize RPL27A distribution within ribosomal substructures

• Live-cell imaging with tagged RPL27A to monitor dynamics during stress responses

• Correlative light and electron microscopy to connect RPL27A localization with ultrastructural features

Single-Cell Technologies:

• Single-cell RNA-seq combined with protein analysis to understand cell-to-cell variability in RPL27A expression and function

• Spatial transcriptomics to map RPL27A expression patterns within tissues

These technological advances will enable more precise dissection of RPL27A's multifaceted roles in normal physiology and disease states.